Determining the impact of Benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (GOAL trial): Study protocol for a randomized controlled trial
Andrea Beaton, Emmy Okello, Daniel Engelman, Anneke Grobler, Amy Scheel, Alyssa DeWyer, Rachel Sarnacki, Isaac Otim Omara, Joselyn Rwebembera, Craig Sable, Andrew Steer
AMERICAN HEART JOURNAL | MOSBY-ELSEVIER | Published : 2019
Rheumatic heart disease (RHD) remains a high prevalence condition in low- and middle-income countries. Most individuals with RHD present late, missing the opportunity to benefit from secondary antibiotic prophylaxis. Echocardiographic screening can detect latent RHD, but the impact of secondary prophylaxis in screen-detected individuals is not known. METHODS/DESIGN: This trial aims to determine if secondary prophylaxis with every-4-week injectable Benzathine penicillin G (BPG) improves outcomes for children diagnosed with latent RHD. This is a randomized controlled trial in consenting children, aged 5 to 17 years in Northern Uganda, confirmed to have borderline RHD or mild definite RHD on ec..View full abstract
The GOAL trial is funded by the Thrasher Research Fund, Gift of Life International, The Karp Family Foundation, and several private donors.